Dr. Sumanta Pal
Urologic Oncologist
2 Podcasts • 1 Course on BackTable
Dr. Sumantra Pal is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team in Los Angeles, California.
Learn from the experiences and expertise of Dr. Sumanta Pal and other leading voices in your specialty on the BackTable app.
Episode # 221 • 18 Mar 2025
Perioperative Therapy for RCC: Updates & Challenges
Sharpen your approach to high-risk renal cell carcinoma (RCC). In this episode of BackTable Urology, guest Dr. Sumanta (Monty) Pal from City of Hope joins host Dr. Aditya Bagrodia to discuss contemporary kidney cancer treatment and the complexities of perioperative therapy.
This podcast is supported by
More from Dr. Sumanta Pal
Loading recent podcasts…
About
Sumanta (Monty) Kumar Pal, M.D., F.A.S.C.O., is an internationally recognized leader in kidney cancer. Dr. Pal entered college at the age of 13 and began medical school at University of California Los Angeles at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he has remained on faculty since 2009. Over that span of time, he has published more than 550 PubMed cited articles that have been featured in prominent journals including The Lancet, Cancer Cell and Nature Medicine.
Dr. Pal maintains one of the largest portfolios of clinical trials for kidney cancer on the West Coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at the Beckman Research Institute of City of Hope and urologists in the Department of Surgery. He is well known for his practice-defining work in rare types of kidney cancer (such as papillary kidney cancer) and is a pioneer in techniques to modulate the gut microbiome to enhance the impact of cancer treatment. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for currently incurable diseases. He is the lead investigator on multiple trials, ranging from early phase 1 experiences to late-stage phase 3 studies.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.